• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

阿替利珠单抗联合疗法获批用于PD-L1阳性三阴性乳腺癌。

Atezolizumab Combo Approved for PD-L1-positive TNBC.

出版信息

Cancer Discov. 2019 May;9(5):OF2. doi: 10.1158/2159-8290.CD-NB2019-038. Epub 2019 Mar 20.

DOI:10.1158/2159-8290.CD-NB2019-038
PMID:30894361
Abstract

The FDA approved atezolizumab plus nab-paclitaxel for patients with locally advanced or metastatic triple-negative breast tumors expressing PD-L1. The combination is the first immunotherapy regimen to earn marketing authorization for any type of breast cancer.

摘要

美国食品药品监督管理局（FDA）批准阿特珠单抗联合白蛋白结合型紫杉醇用于治疗局部晚期或转移性且表达程序性死亡配体1（PD-L1）的三阴性乳腺癌患者。该联合疗法是首个获得任何类型乳腺癌上市许可的免疫治疗方案。

相似文献

1
Atezolizumab Combo Approved for PD-L1-positive TNBC.阿替利珠单抗联合疗法获批用于PD-L1阳性三阴性乳腺癌。
Cancer Discov. 2019 May;9(5):OF2. doi: 10.1158/2159-8290.CD-NB2019-038. Epub 2019 Mar 20.
2
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.阿替利珠单抗联合白蛋白紫杉醇治疗晚期三阴性乳腺癌。
N Engl J Med. 2018 Nov 29;379(22):2108-2121. doi: 10.1056/NEJMoa1809615. Epub 2018 Oct 20.
3
Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions.纳武利尤单抗联合阿替利珠单抗治疗PD-L1阳性转移性三阴性乳腺癌：综述与未来方向
Expert Rev Precis Med Drug Dev. 2020;5(2):59-65. doi: 10.1080/23808993.2020.1730694. Epub 2020 Feb 20.
4
Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer.在晚期三阴性乳腺癌患者中，一线化疗加用阿替利珠单抗的成本效益。
Ther Adv Med Oncol. 2020 May 5;12:1758835920916000. doi: 10.1177/1758835920916000. eCollection 2020.
5
Atezolizumab in the treatment of metastatic triple-negative breast cancer.阿替利珠单抗治疗转移性三阴性乳腺癌。
Expert Opin Biol Ther. 2020 Sep;20(9):981-989. doi: 10.1080/14712598.2020.1769063. Epub 2020 May 25.
6
Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer.靶向免疫治疗联合化疗：三阴性乳腺癌治疗的新临床范例。
Bosn J Basic Med Sci. 2019 Aug 20;19(3):227-233. doi: 10.17305/bjbms.2019.4204.
7
Immunotherapy for Breast Cancer: First FDA Approved Regimen.乳腺癌免疫疗法：首个获美国食品药品监督管理局批准的方案。
Discoveries (Craiova). 2019 Mar 31;7(1):e91. doi: 10.15190/d.2019.4.
8
Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer.病例报告：一份记录阿替利珠单抗在PD-L1阴性三阴性乳腺癌中活性的病例研究文档。
Front Oncol. 2021 Sep 20;11:710596. doi: 10.3389/fonc.2021.710596. eCollection 2021.
9
Atezolizumab for the treatment of triple-negative breast cancer.阿替利珠单抗治疗三阴性乳腺癌。
Expert Opin Investig Drugs. 2019 Jan;28(1):1-5. doi: 10.1080/13543784.2019.1552255. Epub 2018 Dec 1.
10
A review of current progress in triple-negative breast cancer therapy.三阴性乳腺癌治疗的当前进展综述。
Open Med (Wars). 2020 Nov 14;15(1):1143-1149. doi: 10.1515/med-2020-0138. eCollection 2020.

引用本文的文献

1
Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer.醋酸盐通过增强 T 细胞效应功能和增强乳腺癌中的抗肿瘤免疫作用，充当代谢免疫调节剂。
Nat Cancer. 2023 Oct;4(10):1491-1507. doi: 10.1038/s43018-023-00636-6. Epub 2023 Sep 18.
2
Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer.胰岛素样生长因子受体 1（IGF1R）和胰岛素受体（IR）在三阴性乳腺癌中的治疗靶点的临床前评估。
PLoS One. 2023 Mar 15;18(3):e0282512. doi: 10.1371/journal.pone.0282512. eCollection 2023.
3
The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies.
免疫检查点阻断联合肿瘤血管正常化作为一种有前途的乳腺癌治疗策略：临床前和临床研究综述。
Int J Mol Sci. 2023 Feb 6;24(4):3226. doi: 10.3390/ijms24043226.
4
Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies.用小分子化合物靶向三阴性乳腺癌中的调控细胞死亡（RCD）：从分子机制到靶向治疗的再思考视角。
J Hematol Oncol. 2022 Apr 12;15(1):44. doi: 10.1186/s13045-022-01260-0.
5
Engineered implantable vaccine platform for continuous antigen-specific immunomodulation.工程化可植入疫苗平台，用于持续的抗原特异性免疫调节。
Biomaterials. 2022 Feb;281:121374. doi: 10.1016/j.biomaterials.2022.121374. Epub 2022 Jan 18.
6
Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines.基于新兴生物材料的个体化治疗原位癌症疫苗策略。
Biomaterials. 2022 Jan;280:121297. doi: 10.1016/j.biomaterials.2021.121297. Epub 2021 Nov 30.
7
The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.小 G 蛋白 RalA 促进三阴性乳腺癌的进展和转移。
Breast Cancer Res. 2021 Jun 12;23(1):65. doi: 10.1186/s13058-021-01438-3.
8
PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer.PD-L1 肿瘤内在信号及其在三阴性乳腺癌中的治疗意义。
JCI Insight. 2021 Apr 22;6(8):131458. doi: 10.1172/jci.insight.131458.
9
Biomarkers for precision immunotherapy in the metastatic setting: hope or reality?转移性环境中精准免疫治疗的生物标志物：希望还是现实？
Ecancermedicalscience. 2020 Dec 3;14:1150. doi: 10.3332/ecancer.2020.1150. eCollection 2020.
10
Giant Fungated Locally Advanced Breast Carcinoma Responded to Hypofractionated Radiotherapy Combined with Apatinib: A Case Report and Literature Review.巨大溃疡型局部晚期乳腺癌对低分割放疗联合阿帕替尼治疗有效：一例报告及文献综述
Cancer Manag Res. 2021 Jan 22;13:605-611. doi: 10.2147/CMAR.S291029. eCollection 2021.